Matthew P. Ottmer
Keine laufenden Positionen mehr
Profil
Matthew P.
Ottmer worked as Senior VP-Strategy & Emerging Businesses at Biogen, Inc. from 2014 to 2015, followed by a position as Chief Operating Officer at Momenta Pharmaceuticals, Inc. from 2015 to 2017.
He then became President at Bioverativ Therapeutics, Inc. before serving as Chief Operating Officer at Voyager Therapeutics, Inc. from 2017 to 2020.
Ottmer received his undergraduate degree from the University of Michigan and his MBA from Kellogg School of Management.
Ehemalige bekannte Positionen von Matthew P. Ottmer
| Unternehmen | Position | Ende |
|---|---|---|
| VOYAGER THERAPEUTICS, INC. | Chief Operating Officer | 12.02.2020 |
| MOMENTA PHARMACEUTICALS, INC. | Chief Operating Officer | 01.04.2017 |
| BIOGEN INC. | Corporate Officer/Principal | 01.07.2015 |
Bioverativ Therapeutics, Inc.
 Bioverativ Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Bioverativ Therapeutics, Inc. develops pharmaceutical products. It develops medicines for chronic diseases such as hemophilia, anemia, multiple sclerosis, and autoimmune disorders. The company is headquartered in Cambridge, MA. | President | - |
Ausbildung von Matthew P. Ottmer
| University of Michigan | Undergraduate Degree |
| Kellogg School of Management | Masters Business Admin |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 2 |
|---|---|
| BIOGEN INC. | Health Technology |
| VOYAGER THERAPEUTICS, INC. | Health Technology |
| Private Unternehmen | 2 |
|---|---|
Momenta Pharmaceuticals, Inc.
 Momenta Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Momenta Pharmaceuticals, Inc. operates as a biotechnology company that focuses on the discovery and development of novel biologic therapies for the treatment of rare immune-mediated diseases. Its products include the Glatiramer acetate injection and Enoxaparin Sodium injection. The company was founded by Ram Sasisekharan, Paul R. Schimmel, and Ganesh Venkatraman Kaundinya in May 2001 and is headquartered in Cambridge, MA. | Health Technology |
Bioverativ Therapeutics, Inc.
Bioverativ Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Bioverativ Therapeutics, Inc. develops pharmaceutical products. It develops medicines for chronic diseases such as hemophilia, anemia, multiple sclerosis, and autoimmune disorders. The company is headquartered in Cambridge, MA. | Health Technology |
